DOCSLIB.ORG

Skin Aging Handbook

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Skin Aging Handbook SKIN AGING HANDBOOK An Integrated Approach to Biochemistry and Product Development Edited by Nava Dayan Norwich, NY, USA Copyright © 2008 by William Andrew Inc. No part of this book may be reproduced or utilized in any form or by any means, electronic or me- chanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the Publisher. ISBN: 978-0-8155-1584-5 Library of Congress Cataloging-in-Publication Data Skin aging handbook : an integrated approach to biochemistry and product development / edited by Nava Dayan. p. ; cm. -- (Personal care and cosmetic technology) Includes bibliographical references and index. ISBN 978-0-8155-1584-5 (alk. paper) 1. Skin--Aging. 2. Cosmetics. 3. Dermatologic agents. 4. Cosmetic industry. 5. Dermatologic agents industry. I. Dayan, Nava. II. Series. [DNLM: 1. Skin Physiology--drug effects. 2. Aging--drug effects. 3. Chemistry, Pharmaceutical. 4. Cosmetics--economics. 5. Cosmetics--pharmacology. 6. Cosmetics--therapeutic use. WR 102 S62715 2008] QP88.5.S553 2008 612.7’9--dc22 2008009757 Printed in the United States of America This book is printed on acid-free paper. 10 9 8 7 6 5 4 3 2 1 Published by: William Andrew Inc. 13 Eaton Avenue Norwich, NY 13815 1-800-932-7045 www.williamandrew.com Cover Design by Russell Richardson ENVIRONMENTALLY FRIENDLY This book has been printed digitally because this process does not use any plates, ink, chemicals, or press solutions that are harmful to the environment. The paper used in this book has a 30% recycled content. NOTICE To the best of our knowledge the information in this publication is accurate; however the Publisher does not assume any responsibility or liability for the accuracy or completeness of, or consequences arising from, such information. This book is intended for informational purposes only. Mention of trade names or commercial products does not constitute endorsement or recommendation for their use by the Publisher. Final determination of the suitability of any information or product for any use, and the manner of that use, is the sole responsibility of the user. Anyone intending to rely upon any recommendation of materials or procedures mentioned in this publication should be independently satisfied as to such suitability, and must meet all applicable safety and health standards. This book is a memorial to my grandparents Shifra and Yehoshua Hershman, who raised me. They lost their families who were killed by the Nazis during World War II. They will never age. God bless their souls. Nava Dayan Contents Contributors ix Preface xv Part 1 Sociological Implications, Market View and IT Frontiers 1 1 Aging Skin in Sociocultural Perspective 3 Robert L. Rubinstein and Sarah Canham 2 Market Evolution of Topical Anti-aging Treatments 15 Ni’Kita Wilson 3 Computer-Based Age Progression Methodologies 35 Andreas Lanitis Part 2 Biochemical, Pharmacological, and Ethnicity Aspects 53 4 Structural and Biochemical Changes in Aging Skin and Their Impact on Skin Permeability Barrier 55 Rashmi Thakur, Priya Batheja, Diksha Kaushik, and Bozena Michniak 5 Changes in Epidermal Lipids and Sebum Secretion with Aging 91 Philip W. Wertz 6 Skin Disorders of Inflammation and Immune Suppression in Young and Elder: A Special Role for Mast Cells 105 Moran Elishmereni and Francesca Levi-Schaffer 7 Cellular Senescence and Skin Aging 129 Elena Dellambra and Goberdhan P. Dimri 8 Prevention and Treatment of Aging Skin with Topical Antioxidants 149 Karen E. Burke vii viii Contents 9 Skin Aging in the Asian Population 177 Helen Knaggs Part 3 Product Development 203 10 The Use of Natural Compounds and Botanicals in the Development of Anti-Aging Skin Care Products 205 Cindy K. Angerhofer, Daniel Maes, and Paolo U. Giacomoni 11 Approaches to the Development of Cosmetic Products to Counter the Effects of Skin Aging 265 Gopinathan K. Menon, Laurence Dryer, and Robert Kalafsky 12 The Design and Development of Anti-Aging Formulations 291 Domnica Cernasov Part 4 Testing Methodologies 327 13 In Vitro Methods to Screen Materials for Anti-aging Effects 329 Robert W. Holtz 14 Clinical Testing to Uphold an Anti-aging Claim 363 Toni Miller Part 5 Regulatory Aspects 391 15 Cosmetic Anti-aging Formulations—International Regulatory Aspects 393 Azalea P. Rosholt 16 Strategic Regulatory Planning—Key to Success in Anti-aging Cosmetic Product Development 409 Wen Schroeder Glossary 455 Index 483 Contributors Cindy K. Angerhofer Aveda Corporation 4000 Pheasant Ridge Dr. Minneapolis, MN 55449 USA Priya Batheja Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, NJ 08854 USA Karen E. Burke Department of Dermatology Mount Sinai Medical Center One Gustave Levy Place New York, NY 10025 USA Sarah Canham Doctoral Program in Gerontology University of Maryland, Baltimore County 1000 Hilltop Circle Baltimore, MD 21250 USA Domnica Cernasov Coty Inc. Morris Plains, NJ 07950 USA ix x Contributors Elena Dellambra Laboratory of Tissue Engineering and Cutaneous Physiopathology I.D.I.-IRCCS Istituto Dermopatico dell’Immacolata Via dei Castelli Romani, 83/85 Pomezia (Roma) 00040 Italy Goberdhan P. Dimri Division of Cancer Biology and Department of Medicine ENH Research Institute, and Robert H. Lurie Comprehensive Cancer Center Feinberg School of Medicine Northwestern University 1001 University Place Evanston, IL 60201 USA Laurence Dryer As of January 2008: BASF Beauty Care Solutions, Inc. 50 Health Sciences Drive Stony Brook, NY 11790 USA Moran Elishmereni Department of Pharmacology and Experimental Therapeutics, School of Pharmacy Faculty of Medicine The Hebrew University of Jerusalem POB 12065 Jerusalem 91120 Israel Paolo U. Giacomoni The Estée Lauder Companies, Inc. Melville, NY 11747 USA Robert W. Holtz Director of Laboratory Studies BioInnovation Laboratories, Inc. 7220 W. Jefferson Ave., STE 112 Lakewood, CO 80235 USA Contributors xi Robert Kalafsky Avon Products, Inc. Avon Place Suffern, NY 10901 USA Diksha Kaushik Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, NJ 08854 USA Helen Knaggs Nu Skin 75W Center Street Provo, UTAH 84601 USA Andreas Lanitis Department of Multimedia and Graphic Arts Faculty of Communication and Applied Arts Cyprus University of Technology P.O. Box 50329, 3036 Lemesos, Cyprus Francesca Levi-Schaffer Department of Pharmacology and Experimental Therapeutics, School of Pharmacy Faculty of Medicine The Hebrew University of Jerusalem POB 12065 Jerusalem 91120 Israel Daniel Maes The Estée Lauder Companies, Inc. Melville, NY 11747 USA xii Contributors Gopinathan K. Menon As of October 2007: Global R & D, ISP Corporation Wayne, NJ 07470 USA Bozena Michniak Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, NJ 08854 USA Toni Miller Essex Testing Clinic Inc. 799 Bloomfi eld Ave Verona, NJ 07044 USA Azalea P. Rosholt The Cosmetic, Toiletry, and Fragrance Association Washington, DC 20036 USA Robert L. Rubinstein Department of Sociology and Anthropology Erickson School of Aging Studies University of Maryland, Baltimore County 1000 Hilltop Circle Baltimore, MD 21250 USA Wen Schroeder SEKI Cosmeticals 232 E. Carrington Lane Appleton, WI 54913 USA Rashmi Thakur Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, NJ 08854 USA Contributors xiii Philip W. Wertz N450 DSB, Dows Institute University of Iowa Iowa City, IA 52242 USA Ni’Kita Wilson Cosmetech Laboratories, Inc. 39, Plymouth Street, Suite 4 Fairfi eld, NJ 07004 USA Preface Stress, Emotions and Skin Aging The way we perceive or value a person’s physical appearance is very complicated and contains numerous factors such as sociological back- ground, age, personal experience and preferences. It also changes through- out our lifetime as does the weight we attribute to it in our preferential judgment. I remember that as a child I had two very close friends that were sisters. While in the view of many others they were not physically attractive, in my mind they were the most beautiful people I knew. This is because of their sincere care and affection. On the other hand, I had a very close family member that was only centered within her very own issues. Every few years she would perform a different type of plastic surgery, but no matter what the result was, I still never thought of her as a nice or pretty person. In one of the bible books, the book of Kohelet (Ecclesiastes), which is a type of personal biography, the author says: “hevel hachen vesheker hayofi ” meaning (from the Hebrew): charm is deceptive and beauty is vain. In essence, physical appearance may be misleading and illusory. Personally, I know that in time perspective, the way I remember people is not by their appearance, nor by their words, or what they have given or taken from me. In essence, I think and remember them by the way they made me feel. In one of the books I read, I came across an interesting differentiation between public and medical journalism. While the daily public news wishes to bring the shocking, devastating news, medical journals will only rarely publish “bad” unexpected data. If a study failed to prove a hypothesis it will most likely not be published. In this sense, this book is staged beyond pure science–it provides cautious optimism combined with reality. The protestant theologist Reinhold Niebuhr is communicating to God asking him the following: “grant me the courage to change the things I can change, the serenity to accept the things I cannot change and the wisdom to know the difference.” xv xvi Preface I am hoping that this book will provide the reader with a few tools to understand what can or cannot be changed in the process of skin aging and therefore will ease the acceptance of the unchangeable and encourage the further exploring of the processes that may be controlled. In our society there are great social advantages to being attractive. Common stereotypes of elderly people depict them as physically unattrac- tive and sexually undesirable (Koblenzer, 1996).
Load more

Recommended publications
  • Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690
    [Show full text]
  • Glossary for Narrative Writing
    Periodontal Assessment and Treatment Planning Gingival description Color: o pink o erythematous o cyanotic o racial pigmentation o metallic pigmentation o uniformity Contour: o recession o clefts o enlarged papillae o cratered papillae o blunted papillae o highly rolled o bulbous o knife-edged o scalloped o stippled Consistency: o firm o edematous o hyperplastic o fibrotic Band of gingiva: o amount o quality o location o treatability Bleeding tendency: o sulcus base, lining o gingival margins Suppuration Sinus tract formation Pocket depths Pseudopockets Frena Pain Other pathology Dental Description Defective restorations: o overhangs o open contacts o poor contours Fractured cusps 1 ww.links2success.biz [email protected] 914-303-6464 Caries Deposits: o Type . plaque . calculus . stain . matera alba o Location . supragingival . subgingival o Severity . mild . moderate . severe Wear facets Percussion sensitivity Tooth vitality Attrition, erosion, abrasion Occlusal plane level Occlusion findings Furcations Mobility Fremitus Radiographic findings Film dates Crown:root ratio Amount of bone loss o horizontal; vertical o localized; generalized Root length and shape Overhangs Bulbous crowns Fenestrations Dehiscences Tooth resorption Retained root tips Impacted teeth Root proximities Tilted teeth Radiolucencies/opacities Etiologic factors Local: o plaque o calculus o overhangs 2 ww.links2success.biz [email protected] 914-303-6464 o orthodontic apparatus o open margins o open contacts o improper
    [Show full text]
  • Neonatal Intensive Care Drug Therapy Update: a Bibliography
    LWW/JPNN AS310-13 July 28, 2004 23:11 Char Count= 0 J Perinat Neonat Nurs Vol. 18, No. 3, pp. 292–306 c 2004 Lippincott Williams & Wilkins, Inc. Neonatal Intensive Care Drug Therapy Update: A Bibliography Jason Sauberan, PharmD BIBLIOGRAPHY I. Overview A. Clark RH, Bloom BT, Gerstmann DR Medications Used in Neonatal Intensive Care Units—A Descriptive Study [abstract 3047]. In: Program and abstracts of the 2004 Pediatric Academic Societies’ Annual Meeting, San Francisco, CA. B. Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, Berkovitch M. Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol. 2002 Feb;19(2):67–72. C. O’Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002 Nov;110(5):e52. D. Committee on Drugs. American Academy of Pediatrics. Uses of drugs not described in the package insert (off-label uses). Pediatrics. 2002 Jul;110(1 Pt 1):181–3. II. Anti-infectives A. Linezolid 1. Deville JG, Adler S, Azimi PH, Jantausch BA, Morfin MR, Beltran S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S158–63. 2. Vo M, Cirincione BB, Rubino CM, Jungbluth GL. Pharmacokinetics of Linezolid in Neonates and Young Infants [abstract A-1409]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA.
    [Show full text]
  • Product Reference Guide Contents Page
    PRODUCT REFERENCE GUIDE CONTENTS PAGE INTRODUCTION ����������������������������������������������������������������������������������������������������������������������������������������������� 3 PRODUCT INFORMATION ������������������������������������������������������������������������������������������������������������������������������� 4 HOW NATURAL INGREDIENTS WORK ���������������������������������������������������������������������������������������������������������� 5 OUR KEY INGREDIENTS���������������������������������������������������������������������������������������������������������������������������� 6 - 7 PRODUCT SPECIFICATIONS ��������������������������������������������������������������������������������������������������������������������� 8 - 9 MILK CLEANSER �������������������������������������������������������������������������������������������������������������������������������������������� 10 ENZYME GEL CLEANSER ����������������������������������������������������������������������������������������������������������������������������� 11 ENZYME EXFOLIANT POWDER ������������������������������������������������������������������������������������������������������������������� 12 VITAMIN A SERUM ����������������������������������������������������������������������������������������������������������������������������������������� 13 VITAMIN C SERUM ����������������������������������������������������������������������������������������������������������������������������������������� 14 VITAMIN B SERUM
    [Show full text]
  • Application and Review of Pediatric Pharmacotherapy, Sample Chapter
    Application and Review of Pediatric Pharmacotherapy Chapter No. 1 Dated: 29/7/2010 At Time: 16:16:4 Section 1 Neonatal intensive care “Luck is where preparation meets opportunity.” This section consists of 16 medication orders followed by corresponding patient profiles representing pharmacotherapy associated with patients admit- ted to a neonatal intensive care unit. Each patient profile is followed by multiple-choice questions pertaining to the medication order and profile infor- mation. Choose the one best-lettered response to each item. The correct answers are provided at the end of this section. The reader is encouraged to attempt all questions for each case or for the entire section prior to referring to the answers. Moreover, where appropriate, the answer key provides a thor- ough explanation of the correct response and should serve as an additional learning tool for the reader. Application and Review of Pediatric Pharmacotherapy Chapter No. 1 Dated: 29/7/2010 At Time: 16:16:4 2 | Application and Review of Pediatric Pharmacotherapy Medication orders Physician order Patient weight: 2.5 kg Aminophylline 10 mg iv load, then begin 2.5 mg iv q 12 h Obtain theophylline concentration 1 h postinfusion of loading dose Date/time: 12/01/2100 Patient name: Baby Boy Turner Physician: John Craver Patient ID: 111222 Medical profile Patient: Baby Boy Turner Patient weight: 2.5 kg Age: 1d/o Present illness: Apneic episodes Allergies: None Medical history: 33 weeks gestation, Apgar 7 and 9 Labs: pending Medication profile Questions Q1 Which of the following is an acceptable definition of apnea of prematurity? 1 o cessation of breathing for less than 20 s 2 o cessation of breathing for at least 20 s 3 o cessation of breathing for less than 20 s when accompanied by bradycardia A o 1 only B o 3 only C o 1 and 3 only Application and Review of Pediatric Pharmacotherapy Chapter No.
    [Show full text]
  • Caffeine in the Treatment of Pain
    Rev Bras Anestesiol ARTIGOS DE REVISÃO 2012; 62: 3: 387-401 ARTIGOS DE REVISÃO Cafeína para o Tratamento de Dor Cristiane Tavares, TSA 1, Rioko Kimiko Sakata, TSA 2 Resumo: Tavares C, Sakata RK – Cafeína para o Tratamento de Dor. Justificativa e objetivos: A cafeína é uma substância amplamente consumida com efeitos em diversos sistemas e que apresenta farmacoci- nética e farmacodinâmica características, causando interações com diversos medicamentos. O objetivo deste estudo é fazer uma revisão sobre os efeitos da cafeína. Conteúdo: Nesta revisão, são abordados a farmacologia da cafeína, os mecanismos de ação, as indicações, as contraindicações, as doses, as interações e os efeitos adversos. Conclusões: Faltam estudos controlados, randomizados e duplos-cegos para avaliar a eficácia analgésica da cafeína nas diversas síndromes dolorosas. Em pacientes com dor crônica, é necessário ter cautela em relação ao desenvolvimento de tolerância, abstinência e interação medi- camentosa no uso crônico de cafeína. Unitermos: ANALGESIA; DOR; DROGAS, Alcaloide/cafeína. ©2012 Elsevier Editora Ltda. Todos os direitos reservados. INTRODUÇÃO Estrutura química A cafeína foi isolada em 1820, mas a estrutura correta des- A cafeína é um alcaloide presente em mais de 60 espécies ta metilxantina foi estabelecida na última década do século de plantas 4. Sua estrutura molecular pertence a um grupo XIX. Os efeitos não foram claramente reconhecidos até 1981, de xantinas trimetiladas que incluem seus compostos inti- quando o bloqueio de receptores adenosina foi correlacio- mamente relacionados: teobromina (presente no cacau) e nado às propriedades estimulantes da cafeína e de seus teofilina (presente no chá) 1. Quimicamente, esses alcaloides análogos 1. Provavelmente a cafeína é uma das substâncias são semelhantes a purinas, xantinas e ácido úrico, que são psicoativas mais utilizadas no mundo, promovendo efeitos compostos metabolicamente importantes 4.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Actinic Keratoses Final Report
    Actinic Keratoses Final Report Mark Helfand, MD, MPH Annalisa K. Gorman, MD Susan Mahon, MPH Benjamin K.S. Chan, MS Neil Swanson, MD Submitted to the Agency for Healthcare Research and Quality under contract 290-97-0018, task order no. 6 Oregon Health & Science University Evidence-based Practice Center 3181 SW Sam Jackson Park Road Portland, Oregon 97201 May 19, 2001 Actinic Keratoses Structured Abstract Objective: To examine evidence about the natural history and management of actinic keratoses (AKs). Search Strategy: We searched the MEDLINE database from January 1966 to January 2001, the Cochrane Controlled Trials Registry, and a bibliographic database of articles about skin cancer. We identified additional articles from reference lists and experts. Selection Criteria: We selected 45 articles that contained original data relevant to treatment of actinic keratoses, progression of AKs to squamous cell cancer (SCC ), means of identifying a high-risk group, or surveillance of patients with AKs to detect and treat SCCs early in their course. Data Collection and Analysis: We abstracted information from these studies to construct evidence tables. We also developed a simple mathematical model to examine whether estimates of the rate of progression of AK to SCC were consistent among studies. Finally, we analyzed data from the Medicare Statistical System to estimate the frequency of procedures attributable to AK among elderly beneficiaries. Main Results: The yearly rate of progression of an AK in an average-risk person in Australia is between 8 and 24 per 10,000. High-risk individuals with multiple AKs have progression rates as high as 12-30 percent over 3 years.
    [Show full text]
  • Enjoy Every Moment... Fuel Your Cells and Body with the Double Energy Surge of Coq10 and PQQ in MAX-Q10™ ULTRA PQQ
    26th Edition 365 DAY GUARANTEE For a Longer, Healthier Life Enjoy Every Moment... Fuel your cells and body with the double energy surge of CoQ10 and PQQ in MAX-Q10™ ULTRA PQQ. See pages 16-17 s 800.627.9721 www.StopAgingNow.com/Catalog 26th Edition STOP AGING NOW ® Contents For a Longer, Healthier Life Antioxidants ..........................32-33 You have many choices when it comes to your Bladder Health ........................... 41 natural health products, so we're honored that you put your trust in Stop Aging Now. We Blood Pressure ......................12-13 promise we won’t let you down! Blood Sugar ..........................14-15 In the pages ahead, you'll find several new Brain & Memory ........................... 7 ways to improve your health and the health of the ones you love, including your pets. From Coenzyme Q10 ......................16-18 fast relief for joint pain to healthy, glowing skin Collagen ................................28-29 from the inside out, be sure to read about all of our newest breakthrough solutions. Check out Daily Essentials ....................34-35 more premium health products online. Digestion & Detox .................37-39 See back cover for your coupon code. Hair & Body ................................ 31 Heart Support ..........................8-11 Joint & Bone Health ..............22-23 S.A.V.E. with AutoShip Men's Health .........................43-45 Lock In Our Lowest Prices Multinutrient Formulas .........24-25 Natural Pet Care ......................... 46 S ave up to 30% per bottle on every order! Natural Skin Care ....................... 30 utomatically lock in our lowest price and Shop Our A NextLevel Formulas ................... 36 never worry about an increase! Omega-3s ..............................26-27 V ery convenient—set it and forget it, get products on your schedule! NEW Probiotics ..................................
    [Show full text]
  • Advanced Technology with Maximum Versatility for Dermatology & Aesthetic Procedures
    ADVANCED TECHNOLOGY WITH MAXIMUM VERSATILITY FOR DERMATOLOGY & AESTHETIC PROCEDURES Fractional and Non-Fractional Applications Skin Resurfacing Skin Rejuvenation Skin Tightening Scar Remodeling Skin Tags & Benign Skin Lesion Skin Imperfections “The Pixel CO2 is brilliant; it is a must - have device for all dermatologists and plastic surgeons.” Dr. Michael Shochat, MD, Dermatologist. 2 | ALMA Pixel CO2 ALMA The carbon dioxide (CO2) laser has been known to provide some of the most dramatic, age-defying results in the treatment of challenging skin imperfections including wrinkles, fine lines, photodamage, uneven skin tone and skin laxity, as well as in scar treatment, skin tags and benign tumors. Using the power of the CO2 laser, the optimal mix of ablative and thermal effects and an array of applicators and treatment modes for highly tailored procedures, Alma’s Pixel CO2 brings unparalleled precision and innovation to the field of dermatology and plastic surgery. Alma Pixel CO2 is a highly flexible system for char-free tissue ablation, vaporization, excision, incision and coagulation of soft tissue. It allows physicians full control of treatment parameters, including level and depth of ablation and thermal control via pulse duration and mode of energy delivery. This versatility maximizes precision and treatment results while minimizing unnecessary tissue damage. The CO2 laser uses a 10,600nm wavelength, which is ideal for collagen matrix renewal and an optimal choice for treating an extensive range of dermatological issues. The CO2 laser has the ability to perform efficient, highly precise fractional and non-fractional laser treatments using the widest assortment of advanced applicators. With powerful performance and hundreds of treatment options, Alma Pixel CO2 opens the door to new possibilities in dermatological and surgical treatments.
    [Show full text]
  • Single Laboratory Validation of a Quantitative Core Shell-Based LC
    Single Laboratory Validation of a Quantitative Core Shell-Based LC Separation for the Evaluation of Silymarin Variability and Associated Antioxidant Activity of Pakistani Ecotypes of Milk Thistle (Silybum Marianum L.) Samantha Drouet, Bilal Haider Abbasi, Annie Falguieres, Waqar Ahmad, S. Sumaira, Clothilde Ferroud, Joël Doussot, Jean Vanier, Christophe Hano To cite this version: Samantha Drouet, Bilal Haider Abbasi, Annie Falguieres, Waqar Ahmad, S. Sumaira, et al.. Single Laboratory Validation of a Quantitative Core Shell-Based LC Separation for the Evaluation of Sily- marin Variability and Associated Antioxidant Activity of Pakistani Ecotypes of Milk Thistle (Silybum Marianum L.). Molecules, MDPI, 2018, 23 (4), pp.904. 10.3390/molecules23040904. hal-02538464 HAL Id: hal-02538464 https://hal.archives-ouvertes.fr/hal-02538464 Submitted on 9 Apr 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License molecules Article Single Laboratory Validation of a Quantitative Core Shell-Based
    [Show full text]
  • Silychristin Derivatives Conjugated with Coniferylalcohols from Silymarin and Their Pancreatic Α-Amylase Inhibitory Title Activity
    Silychristin derivatives conjugated with coniferylalcohols from silymarin and their pancreatic α-amylase inhibitory Title activity Author(s) Kato, Eisuke; Kushibiki, Natsuka; Satoh, Hiroshi; Kawabata, Jun Natural Product Research, 34(6), 759-765 Citation https://doi.org/10.1080/14786419.2018.1499639 Issue Date 2020-03-18 Doc URL http://hdl.handle.net/2115/80605 This is an Accepted Manuscript of an article published by Taylor & Francis in Natural Product Research on Rights Mar.18.2020, available online: http://www.tandfonline.com/10.1080/14786419.2018.1499639. Type article (author version) File Information EK_NatProdRes_milk_thistle_w_supplement.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP *Post-print manuscript This document is the unedited Author's version of a Submitted Work that was subsequently accepted for publication in “Natural Product Research” published by Taylor & Francis after peer review. To access the final edited and published work see https://doi.org/10.1080/14786419.2018.1499639 Graphical abstract 1 RESEARCH ARTICLE Silychristin derivatives conjugated with coniferylalcohols from silymarin and their pancreatic α-amylase inhibitory activity Eisuke Katoa*, Natsuka Kushibikib, Hiroshi Satohc and Jun Kawabataa aDivision of Fundamental AgriScience and Research, Research Faculty of Agriculture, Hokkaido University, Kita-ku, Sapporo, Hokkaido 060-8589, Japan bDivision of Applied Bioscience, Graduate School of Agriculture, Hokkaido University, Kita-ku, Sapporo, Hokkaido 060-8589, Japan cNissei Bio Co. Ltd., Eniwa, Hokkaido, 061-1374, Japan *Corresponding author. Eisuke Kato, 1Division of Fundamental AgriScience and Research, Research Faculty of Agriculture, Hokkaido University, Kita-ku, Sapporo, Hokkaido 060-8589, Japan; Tel/Fax: +81 11 706 2496; e-mail: [email protected] 2 Abstract Silymarin is a mixture of flavonolignans extracted from the fruit of Silybum marianum (milk thistle).
    [Show full text]